A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (Phase 3)

syn66496325

A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Created By Orca Service orca-service

url: https://fair.dap.c-path.org/#/data/datasets/fv2_als1002_2025_03_25
title: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (Phase 3)
sameAs: cpath:1845
source: Critical Path Institute
creator: Cytokinetics, Inc.
species: Homo sapiens
subject: amyotrophic lateral sclerosis
keywords: Amyotrophic Lateral Sclerosis ALS CK-2127107 Reldesemtiv COURAGE-ALS
publisher: Critical Path Institute
collection: ALS Knowledge Portal
contributor: Cytokinetics

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (Phase 3)

syn66496325

Drop files to upload

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (Phase 3) page is loading…